论文部分内容阅读
目的 2 -氯乙基 - 3-肌氨酸酰胺 - 1-亚硝脲 (Sar CNU)是一类新型亚硝脲类抗癌药 ,探讨其对 MGMT耐药基因高表达胶质瘤的疗效。方法 腹腔注射 Sar CNU(5 0 0 mg/ m2 ) ,BCNU(4 0 mg/ m2 ) ,O6 - BG(30 0 mg/ m2 ) ,观察其在动物体内胶质瘤的生长情况。结果 Sar CNU处理组生长延缓 34.7天 ,BCNU组生长延缓 2 0 .75天 ,差异有显著性 ,Sar CNU与 O6 - BG联合处理组与 Sar CNU组差异无显著性 (P>0 .10 )。结论 新型亚硝脲类药物 Sar CNU较 BCNU能更好地抑制 MGMT高表达的人脑胶质瘤的生长。
The purpose of 2-chloroethyl-3-sarcosine-1-nitrosourea (Sar CNU) is a new class of nitrosourea anticancer drugs, to explore its MGMT resistance gene overexpression of glioma curative effect. Methods SarCNU (500 mg / m2), BCNU (40 mg / m2), and O6 - BG (300 mg / m2) were injected intraperitoneally to observe the growth of glioma in animals. Results The growth of Sar CNU group was delayed by 34.7 days and the growth of BCNU group was delayed by 20.7 days. There was no significant difference between Sar CNU and O6 - BG group and Sar CNU group (P> 0.10). Conclusion Sar CNU, a novel nitrosourea agent, can better inhibit the growth of MGMT-overexpressing human glioma than BCNU.